Published in J Psychiatr Res on June 22, 1999
Likelihood formulation of parent-of-origin effects on segregation analysis, including ascertainment. Am J Hum Genet (2001) 0.91
Evidence for linkage and association of GABRB3 and GABRA5 to panic disorder. Neuropsychopharmacology (2014) 0.77
Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet (1999) 1.98
Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry (2012) 1.57
Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. Arch Gen Psychiatry (2001) 1.56
Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem Funct (2002) 1.40
[18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry (1995) 1.23
The Iowa Personality Disorder Screen: development and preliminary validation of a brief screening interview. J Pers Disord (1999) 1.17
Decision-making heterogeneity in obsessive-compulsive disorder: ventromedial prefrontal cortex function predicts different treatment outcomes. Neuropsychologia (2002) 1.15
Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol (2001) 1.09
Disorganization of anatomical connectivity in obsessive compulsive disorder: a multi-parameter diffusion tensor imaging study in a subpopulation of patients. Neurobiol Dis (2009) 1.05
Sensitivity to 35% CO2 in healthy first-degree relatives of patients with panic disorder. Am J Psychiatry (1995) 1.02
The cooccurrence of DSM-III-R personality disorders. J Pers Disord (1998) 1.01
Complex segregation analysis for obsessive compulsive disorder and related disorders. Am J Med Genet (1999) 0.98
Age at onset of panic disorder: influence of familial liability to the disease and of childhood separation anxiety disorder. Am J Psychiatry (1995) 0.96
Temperament dimensions explain the comorbidity of psychiatric disorders. Compr Psychiatry (1996) 0.94
Serotonin transporter linked polymorphic region in anorexia nervosa and bulimia nervosa. Mol Psychiatry (2000) 0.93
The unipolar-bipolar dichotomy and the response to sleep deprivation. Psychiatry Res (1998) 0.93
First-cycle REM density in never-depressed subjects with borderline personality disorder. Biol Psychiatry (1999) 0.93
Plasma interleukin-1 beta and tumor necrosis factor concentrations in obsessive-compulsive disorders. Biol Psychiatry (1997) 0.92
228Ra/226Ra/224Ra and 87Sr/86Sr isotope relationships for determining interactions between ground and river water in the upper Rhine valley. J Environ Radioact (2001) 0.90
Hypersensitivity to inhalation of carbon dioxide and panic attacks. Psychiatry Res (1995) 0.90
Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment. Eur Neuropsychopharmacol (1997) 0.88
Ambulatory polysomnography of never-depressed borderline subjects: a high-risk approach to rapid eye movement latency. Biol Psychiatry (1993) 0.87
Family history of panic disorder and hypersensitivity to CO2 in patients with panic disorder. Am J Psychiatry (1996) 0.87
A family study of schizotypal disorder. Schizophr Bull (1995) 0.86
Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol (1998) 0.86
Asthma and panic attacks. Biol Psychiatry (1997) 0.86
Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder. Psychiatr Genet (1997) 0.86
Determination of 228Ra, 226Ra and 224Ra in natural water via adsorption on MnO2-coated discs. J Environ Radioact (2001) 0.86
An association study between 5-HTTLPR polymorphism, COMT polymorphism, and Tourette's syndrome. Psychiatry Res (2000) 0.85
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J (2002) 0.85
Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. Eur Neuropsychopharmacol (1999) 0.85
Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease. Semin Thromb Hemost (1996) 0.85
The 5-HT(2A) -1438G/A polymorphism in anorexia nervosa: a combined analysis of 316 trios from six European centres. Mol Psychiatry (2002) 0.85
Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinology (2001) 0.85
Plasma interleukin-1 beta concentrations in panic disorder. Psychiatry Res (1994) 0.85
Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. Psychoneuroendocrinology (1995) 0.84
Laboratory response of patients with panic and obsessive-compulsive disorders to 35% CO2 challenges. Am J Psychiatry (1995) 0.84
Vestibular testing in patients with panic disorder and chronic dizziness. Acta Otorhinolaryngol Ital (2007) 0.84
Obsessive compulsive disorder and mood disorders: a family study. Am J Med Genet (1995) 0.84
Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry (2004) 0.84
Panic disorder: the role of the balance system. J Psychiatr Res (2001) 0.84
Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry (1996) 0.83
EEG power modifications in panic disorder during a temporolimbic activation task: relationships with temporal lobe clinical symptomatology. J Neuropsychiatry Clin Neurosci (1993) 0.83
Physiological and behavioral responses to minor stressors in offspring of patients with panic disorder. J Psychiatr Res (1997) 0.83
Frontal lobe dysfunction in schizophrenia and obsessive-compulsive disorder: a neuropsychological study. Brain Cogn (1995) 0.83
Complex segregation analysis of obsessive-compulsive disorder in 141 families of eating disorder probands, with and without obsessive-compulsive disorder. Am J Med Genet (2000) 0.83
A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry (2001) 0.82
Carbon dioxide/oxygen challenge test in panic disorder. Psychiatry Res (1994) 0.82
5HT2C CYS23/SER23 polymorphism is not associated with obsessive-compulsive disorder. Psychiatry Res (1998) 0.81
Frontal lobe dysfunction in obsessive-compulsive disorder and major depression: a clinical-neuropsychological study. Psychiatry Res (1998) 0.81
The 35% CO2 challenge test in patients with social phobia. Psychiatry Res (1997) 0.81
Combined family trio and case-control analysis of the COMT Val158Met polymorphism in European patients with anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet (2004) 0.81
Menstrual cycle-related sensitivity to 35% CO2 in panic patients. Biol Psychiatry (1995) 0.81
Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol (1997) 0.81
Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy. Psychiatry Res (1999) 0.81
Panic attacks: a twin study. Psychiatry Res (1997) 0.80
Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Biol Psychiatry (1999) 0.80
Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol (1997) 0.80
MHPG, amitriptyline and affective disorders. A longitudinal study. Int Pharmacopsychiatry (1976) 0.80
Neurocognitive functioning in bulimia nervosa: the role of neuroendocrine, personality and clinical aspects. Psychol Med (2010) 0.80
Simultaneous determination of clomipramine and its desmethyl and hydroxy metabolites in plasma of patients by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.80
Personality features related to generalized anxiety disorder. Compr Psychiatry (1990) 0.80
Dizziness, migrainous vertigo and psychiatric disorders. J Laryngol Otol (2009) 0.79
Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation. Biol Psychiatry (1997) 0.79
The HLA system and the clinical response to treatment with chlorpromazine. Br J Psychiatry (1976) 0.79
Lack of association between obsessive-compulsive disorder and the dopamine D3 receptor gene: some preliminary considerations. Am J Med Genet (1994) 0.79
Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. J Clin Psychiatry (1999) 0.79
Alpha reactivity in schizophrenia and in schizophrenic spectrum disorders: demographic, clinical and hemispheric assessment. Int J Psychophysiol (1989) 0.79
Relationship between obsessive-compulsive personality disorder and obsessive-compulsive disorder. Compr Psychiatry (1997) 0.79
Follow-up of obsessive-compulsive patients treated with proserotonergic agents. J Clin Psychopharmacol (1995) 0.78
A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease. Semin Thromb Hemost (1991) 0.78
Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. Psychoneuroendocrinology (1995) 0.78
Cardiac autonomic function during sleep of never-depressed borderline subjects: a pilot study. J Psychiatr Res (1996) 0.78
A neural network approach to the outcome definition on first treatment with sertraline in a psychiatric population. Artif Intell Med (2001) 0.78
A psychometric-genetic study of schizotypal disorder. Schizophr Res (1999) 0.78
A neuropsychological study of dissociation in cortical and subcortical functioning in obsessive-compulsive disorder by Tower of Hanoi task. Brain Cogn (2001) 0.78
Human nuclear transcription factor gene CREM: genomic organization, mutation screening, and association analysis in panic disorder. Am J Med Genet B Neuropsychiatr Genet (2003) 0.78
Psychiatric disorders in the families of schizotypal subjects. Schizophr Bull (1991) 0.78
An investigation of the co-occurrence of panic and somatization disorders through temperamental variables. Psychosom Med (1999) 0.78
The structure of DSM-III-R schizotypal personality disorder diagnosed by direct interviews. Schizophr Bull (1997) 0.78
Increased concentrations of various amino acids in schizophrenic patients. Evidence for heterozygosity effects? Hum Genet (1987) 0.77
Effect of the catechol-O-methyltransferase val(158)met genotype on children's early phases of facial stimuli processing. Genes Brain Behav (2006) 0.77
Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol (1997) 0.77
Psychoimmunoendocrine aspects of panic disorder. Neuropsychobiology (1992) 0.77
Subclinical impairment of lung airways in patients with panic disorder. Biol Psychiatry (1994) 0.77
A long-term prospective evaluation of first-degree relatives of panic patients who underwent the 35% CO2 challenge. Biol Psychiatry (1999) 0.77
EEG power modifications in obsessive-compulsive disorder during olfactory stimulation. Biol Psychiatry (1996) 0.77
Anticipation of age at onset in panic disorder. Am J Psychiatry (1998) 0.77
Abnormal pattern of cortical activation associated with voluntary movement in obsessive-compulsive disorder: an EEG study. Am J Psychiatry (2001) 0.77
DSM-III-R personality disorders in panic and obsessive-compulsive disorder: a comparison study. Compr Psychiatry (1992) 0.77